Rezivertinib
Rezivertinib (BPI-7711) is an orally active, highly selective and irreversible third-generation EGFR tyrosine kinase inhibitor (TKI) . Rezivertinib exhibits high potency against the common activation EGFR and the resistance T790M mutations. Rezivertinib has excellent central nervous system (CNS) penetration and has antitumor activity[1][2].
Product Specifications
CAS Number
1835667-12-3
Product Name Alternative
BPI-7711
UNSPSC
12352005
Target
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/rezivertinib.html
Purity
99.62
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
C=CC(NC1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OC)C=C1OCCN(C)C)=O
Molecular Formula
C27H30N6O3
Molecular Weight
486.57
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
EGFR/ErbB1/HER1
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Nucleophosmin (Acute Myeloid Leukemia Marker) (rNPM1/1901), CF405S conjugate, 0.1mg/mL
BARX1 (Prognostic Biomarker in Hepatocellular Carcinoma) (BARX1/2760), CF405S conjugate, 0.1mg/mL
DOG-1 / TMEM16A (Gastrointestinal Stromal Tumor Marker) (DG1/1485), CF568 conjugate, 0.1mg/mL
